Intra-Cellular Therapies’ antipsychotic medication Caplyta has demonstrated commercial success in recent phase 3 trial data. Trial data demonstrated Caplyta’s efficacy in delaying relapse in schizophrenia patients, achieving a 63% risk reduction compared to placebo. The trial showed improved treatment discontinuation rates and supported long-term use. Initially FDA-approved in 2019 for schizophrenia, Caplyta also treats bipolar depression and is poised for expansion into major depressive disorder (MDD) after positive phase 3 trials. Sales surged 39% year-over-year, surpassing market growth. The potential MDD approval could vastly expand its market reach, covering up to 80% of antipsychotic prescriptions for related disorders. Intra-Cellular has increased its sales force to capitalize on this momentum and is conducting further studies to solidify Caplyta’s efficacy across diverse patient groups.

To read more, click here.

[Source: Fierce Pharma, November 5, 2024.]